Recruiting
Phase 1
Phase 2

RSV/hMPV Vaccine

Sponsor:

GlaxoSmithKline

Code:

NCT07628049

Conditions

Respiratory Syncytial Virus Infections+Metapneumovirus

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

RSV/hMPV_V low dose vaccine

RSV/hMPV_V medium dose vaccine

RSV/hMPV_V high dose vaccine

RSV/hMPV_W low dose vaccine

RSV/hMPV_W medium dose vaccine

Study Details

Brief summary:

The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.

Conditions

Respiratory Syncytial Virus Infections+Metapneumovirus

Study ID

NCT07628049

Start date

Jun 5, 2026

Status verified date

Sep, 2026

Completion date

Apr 5, 2029

Anticipated

Primary completion date

Apr 5, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Written informed consent obtained from the participant prior to performance of any study-specific procedure.
  • Participants who can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits, ability to access and utilize a phone or other electronic communications).
  • Body Mass Index (BMI) between 18 kg/m\^2 and 33 kg/m\^2, inclusive.

Specific inclusion criteria for OA

  • A male or female between and including, 60 to 80 YOA at the time of the study intervention administration.
  • Healthy participants or medically stable patients as established by medical history and physical examination.

Specific inclusion criteria for YA

  • A male or female participant between and including 18 to 49 YOA at the time of the study intervention administration.
  • Healthy participants as established by medical history, clinical examination and laboratory assessment at screening.
  • Participants of non-childbearing potential may be enrolled in the clinical study.
  • Participant of childbearing potential may be enrolled in the study if the participant:

  • has used two methods of contraception, at-least one of which must be a highly effective method, and the other being male condom for male sexual partners of POCBP to be used during sexual intercourse (with the exception of sexual abstinence, vasectomized partner and male partner who has been sterilized, in which case contraception is not required), at-least 30 days prior to study intervention administration, and has agreed to continue using above contraception requirements for 8 weeks after study intervention administration.
  • has a negative serum pregnancy test at screening and negative urine pregnancy test prior to study intervention administration on Day 1.

Exclusion criteria:

Participants are excluded from participating in the study if any of the following criteria apply:

  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
  • Any medical condition that in the judgment of the investigator would make IM injection unsafe.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., current malignancy, HIV) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat autoimmune disorders), based on medical history and physical examination (no laboratory testing required).
  • Acute or unstable chronic pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination and medical history.
  • Documented history of HIV, HBV, HCV infection.
  • History of RSV and /or hMPV-associated illness, diagnosed serologically or microbiologically in the last 12 months.
  • Recurrent history or uncontrolled neurological disorders or seizures, or history of demyelinating conditions (including GBS).
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease).
  • Use of any investigational or non-registered product (drug, vaccine, or invasive medical device) other than the study intervention during the period beginning 30 days before study intervention administration (Day -29 to Day 1), or within 5 half-lives, whichever is longer, or their planned use during the study period.
  • Has previously received an investigational or approved vaccine or antibody for prevention of hMPV and/or RSV-associated diseases.
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.

  • Up to 3 months prior to the study intervention administration:

  • For corticosteroids, this will mean prednisone equivalent >=20 mg/day for adult participants. Inhaled, topical and intra-articular steroids are allowed.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives.
  • Up to 6 months prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication.
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention.
  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Participation of any study personnel or their immediate dependents, family, or household members.
  • Planned move during the study period that will prohibit participating in the study until study end.
  • Bedridden participants.

Specific exclusion criteria for OA population

  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period beginning 30 days before study intervention administration (Day - 29 to Day 1), or their planned use 30 days after study intervention administration, with the exception of inactivated, subunit and split influenza vaccines or COVID-19 vaccines which can be administered up to 14 days before or from 14 days after the study intervention administration.
  • At screening (Phase 1 only), participants with:

  • >=Grade 2 abnormalities for the following parameters, regardless of clinical significance, should be excluded:

  • Hematologic: hemoglobin (Hb), white blood cells (WBC), platelets, absolute cell counts of lymphocytes, neutrophils, eosinophils,
  • Biochemical: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), bilirubin, creatinine, blood urea nitrogen (BUN).
  • Grade 1/mild hematologic and/ or biochemical laboratory abnormalities that are not clinically significant in the clinical judgment of the investigator, may be included.

Specific exclusion criteria for YA population

  • Pregnant or lactating participant.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions for 8 weeks after study intervention administration.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period beginning 30 days before study intervention administration (Day - 29 to Day 1), or their planned use 30 days after study intervention administration.
  • At screening, participants with:

  • >=Grade 2 abnormalities for the following parameters, regardless of clinical significance, should be excluded:

  • Hematologic: Hb, WBC, platelets, absolute cell counts of lymphocytes, neutrophils, eosinophils,
  • Biochemical: ALT, AST, ALP, bilirubin, creatinine, BUN.
  • Grade 1/mild hematologic and/ or biochemical laboratory abnormalities that are not clinically significant in the clinical judgment of the investigator, may be included.
  • Use of any medication, including prescription and non-prescription drugs or herbal remedies (such as St. John's wort) beginning 14 days (or 5 half-lives) prior to study intervention administration and/or planned administration during the study period. Certain medications may be permitted (Eg: contraceptives for POCBP).

Study Design

Enrollment

1456 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: RSV/hMPV X low dose Ph1 Younger Adults (YA) Group

YA participants receive a single dose of RSV/hMPV\_X low dose vaccine in Phase 1, at Day 1.

experimental: RSV/hMPV X medium dose Ph1 YA Group

YA participants receive a single dose of RSV/hMPV\_X medium dose vaccine in Phase 1, at Day 1.

experimental: RSV/hMPV X high dose Ph1 YA Group

YA participants receive a single dose of RSV/hMPV\_X high dose vaccine in Phase 1, at Day 1.

experimental: hMPV Y high dose Ph1 YA Group

YA participants receive a single dose of hMPV\_Y high dose vaccine in Phase 1, at Day 1.

experimental: hMPV Z low dose Ph1 YA Group

YA participants receive a single dose of hMPV\_Z low dose vaccine in Phase 1, at Day 1.

experimental: hMPV Z medium dose Ph1 YA Group

YA participants receive a single dose of hMPV\_Z medium dose vaccine in Phase 1, at Day 1.

experimental: hMPV Z high dose Ph1 YA Group

YA participants receive a single dose of hMPV\_Z high dose vaccine in Phase 1, at Day 1.

active comparator: Control Vaccine Ph1 YA Group

YA participants receive a single dose of control vaccine in Phase 1, at Day 1.

placebo comparator: Placebo Ph1 YA Group

YA participants receive a single dose of placebo in Phase 1, at Day 1.

experimental: RSV/hMPV V low dose Ph1 and Ph2 Older Adults (OA) Group

OA participants receive a single dose of RSV/hMPV\_V low dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: RSV/hMPV V medium dose Ph1 and Ph2 OA Group

OA participants receive a single dose of RSV/hMPV\_V medium dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: RSV/hMPV V high dose Ph1 and Ph2 OA Group

OA participants receive a single dose of RSV/hMPV\_V high dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: RSV/hMPV W low dose Ph1 and Ph2 OA Group

OA participants receive a single dose of RSV/hMPV\_W low dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: RSV/hMPV W medium dose Ph1 and Ph2 OA Group

OA participants receive a single dose of RSV/hMPV\_W medium dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: RSV/hMPV W high dose Ph1 and Ph2 OA Group

OA participants receive a single dose of RSV/hMPV\_W high dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: RSV/hMPV X low dose Ph1 and Ph2 OA Group

OA participants receive a single dose of RSV/hMPV\_X low dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: RSV/hMPV X medium dose Ph1 and Ph2 OA Group

OA participants received a single dose of RSV/hMPV\_X medium dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: RSV/hMPV X high dose Ph1 and Ph2 OA Group

OA participants receive a single dose of RSV/hMPV\_X high dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: hMPV Y low dose Ph1 OA Group

OA participants receive a single dose of hMPV\_Y low dose vaccine in Phase 1, at Day 1.

experimental: hMPV Y medium dose Ph1 and Ph2 OA Group

OA participants receive a single dose of hMPV\_Y medium dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: hMPV Y high dose Ph1 and Ph2 OA Group

OA participants receive a single dose of hMPV\_Y high dose vaccine in both Phase 1 and Phase 2, at Day 1.

experimental: hMPV Z low dose Ph1 OA Group

OA participants receive a single dose of hMPV\_Z low dose vaccine in Phase 1, at Day 1.

experimental: hMPV Z medium dose Ph1 OA Group

OA participants receive a single dose of hMPV\_Z medium dose vaccine in Phase 1, at Day 1.

experimental: hMPV Z high dose Ph1 OA Group

OA participants receive a single dose of hMPV\_Z high dose vaccine in Phase 1, at Day 1.

active comparator: Control Vaccine Ph1 and Ph2 OA Group

OA participants receive a single dose of control vaccine in both Phase 1 and Phase 2, at Day 1.

placebo comparator: Placebo Ph1 and Ph2 OA Group

OA participants receive a single dose of placebo in both Phase 1 and Phase 2, at Day 1.

Interventions

RSV/hMPV V low dose vaccine

RSV/hMPV\_V low dose vaccine administered intramuscularly.

RSV/hMPV V medium dose vaccine

RSV/hMPV\_V medium dose vaccine administered intramuscularly.

RSV/hMPV V high dose vaccine

RSV/hMPV\_V high dose vaccine administered intramuscularly.

RSV/hMPV W low dose vaccine

RSV/hMPV\_W low dose vaccine administered intramuscularly.

RSV/hMPV W medium dose vaccine

RSV/hMPV\_W medium dose vaccine administered intramuscularly.

RSV/hMPV W high dose vaccine

RSV/hMPV\_W high dose vaccine administered intramuscularly.

RSV/hMPV X low dose vaccine

RSV/hMPV\_X low dose vaccine administered intramuscularly.

RSV/hMPV X medium dose vaccine

RSV/hMPV\_X medium dose vaccine administered intramuscularly.

RSV/hMPV X high dose vaccine

RSV/hMPV\_X high dose vaccine administered intramuscularly.

hMPV Y low dose vaccine

hMPV\_Y low dose vaccine administered intramuscularly.

hMPV Y medium dose vaccine

hMPV\_Y medium dose vaccine administered intramuscularly.

hMPV Y high dose vaccine

hMPV\_Y high dose vaccine administered intramuscularly.

hMPV Z low dose vaccine

hMPV\_Z low dose vaccine administered intramuscularly.

hMPV Z medium dose vaccine

hMPV\_Z medium dose vaccine administered intramuscularly.

hMPV Z high dose vaccine

hMPV\_Z high dose vaccine administered intramuscularly.

Control vaccine

Control vaccine administered intramuscularly.

Placebo

Placebo administered intramuscularly.

Primary outcome measure

  • Number of Participants Reporting Solicited Administration Site Events [ Time Frame: Day 1 to Day 7 ]
  • Number of Participants Reporting Solicited Systemic Events [ Time Frame: Day 1 to Day 7 ]
  • Number of Participants Reporting Unsolicited Adverse Events (AEs) [ Time Frame: Day 1 to Day 30 ]
  • Number of Participants Reporting Medically Attended Adverse Events (MAAEs) [ Time Frame: Day 1 to Month 12 ]
  • Number of Participants Reporting Potential immune-mediated disorders (pIMDs) [ Time Frame: Day 1 to Month 12 ]
  • Number of Participants Reporting Serious Adverse Events (SAEs) [ Time Frame: Day 1 to study end [Month 24 for OA groups (only the selected formulation group & its comparators) and Month 12 for all other YA groups & OA groups] ]
  • Number of Participants Reporting Hematological and Biochemical Laboratory Abnormalities [ Time Frame: At Day 1 (pre-vaccination) in Phase 1 groups ]
  • Number of Participants Reporting Hematological and Biochemical Laboratory Abnormalities [ Time Frame: At Day 8 (post-vaccination) in Phase 1 groups ]

Central Contacts and Locations

Central contacts

US GSK Clinical Trials Call Center

877-379-3718GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center

+44 (0) 20 89904466GSKClinicalSupportHD@gsk.com

Locations

GSK Investigational Site

Recruiting

Stockbridge, Georgia, United States, 30281-9054

Contacts

US GSK Clinical Trials Call Center

877-379-3718GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Centre

+44 (0) 20 8990 4466GSKClinicalSupportHD@gsk.com

Principal Investigator:

Jon Finley

GSK Investigational Site

Recruiting

Lenexa, Kansas, United States, 66219

Contacts

US GSK Clinical Trials Call Center

877-379-3718GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Centre

+44 (0) 20 8990 4466GSKClinicalSupportHD@gsk.com

Principal Investigator:

Thomas Kreamer

GSK Investigational Site

Recruiting

Seattle, Washington, United States, 98104-2725

Contacts

US GSK Clinical Trials Call Center

877-379-3718GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Centre

+44 (0) 20 8990 4466GSKClinicalSupportHD@gsk.com

Principal Investigator:

Nicole Ehrhardt

More Information

Sponsor

GlaxoSmithKline

Last update posted

Oct 1, 2026

Last verified

Sep, 2026

Keywords

  • Safety
  • Reactogenicity
  • Immunogenicity
  • Respiratory syncytial virus (RSV)
  • Human metapneumovirus (hMPV)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-09. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2026-10-01. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.